chlorpheniramine maleate; hydrocodone bitartrate
Drug data last refreshed 5h ago · AI intelligence enriched 8h ago
VITUZ is a fixed-dose oral solution combining chlorpheniramine maleate (antihistamine) and hydrocodone bitartrate (opioid), indicated for cough and upper respiratory symptoms. This combination product leverages both antihistaminic and antitussive mechanisms to manage cough associated with allergies or minor respiratory conditions. The product represents a legacy combination therapy approach now facing significant regulatory and commercial scrutiny due to opioid safety concerns.
Product is at peak lifecycle stage with moderate competitive pressure (30); brand management focus likely centers on defensive positioning and market retention rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VITUZ offers limited career growth opportunities given zero linked job openings and peak lifecycle status with no active clinical development. Career value is primarily in defensive commercial strategy, regulatory compliance, and risk management in a constrained opioid market environment.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.